GO:0009013 succinate-semialdehyde dehydrogenase [NAD(P)+] activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0009013 describes the enzymatic activity that converts succinate semialdehyde to succinate using NAD+ or NADP+ as a cofactor.
• The reaction is a key step in the GABA catabolic pathway, linking neurotransmitter degradation to cellular energy metabolism.
• Enzymes with this activity belong to the aldehyde dehydrogenase superfamily and are found across bacteria, plants, and animals [1,2,4].
• Deficiency in succinate-semialdehyde dehydrogenase activity causes succinic semialdehyde dehydrogenase deficiency, a rare neurometabolic disorder [7,8].
• The activity can be regulated by oxidative stress and lipid peroxidation products, which inhibit the enzyme.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of this activity in disease and metabolism [6,7].
Description
Succinate-semialdehyde dehydrogenase [NAD(P)+] activity (GO:0009013) is a molecular function that catalyzes the oxidation of succinate semialdehyde to succinate, using either NAD+ or NADP+ as an electron acceptor. This reaction is a critical step in the catabolism of gamma-aminobutyric acid (GABA), the major inhibitory neurotransmitter in the mammalian central nervous system. The enzyme responsible, often encoded by ALDH5A1 in humans, is a member of the aldehyde dehydrogenase superfamily and is highly conserved from bacteria to humans [1,7]. Researchers study this activity to understand neurotransmitter turnover, energy homeostasis, and the pathophysiology of neurometabolic disorders [6,8]. The reaction catalyzed by GO:0009013 is reversible in vitro but physiologically favors succinate formation, thereby feeding into the tricarboxylic acid (TCA) cycle. In bacteria such as Salmonella typhimurium and Escherichia coli, distinct NAD- and NADP-specific enzymes have been characterized, highlighting the versatility of this activity [1,4]. In plants, the enzyme has been purified from potato tubers, suggesting a role in stress responses and amino acid metabolism. The clinical importance of this activity is underscored by succinic semialdehyde dehydrogenase deficiency, an autosomal recessive disorder caused by mutations in ALDH5A1 that lead to accumulation of GABA and succinate semialdehyde [7,8]. Given its central role in metabolism and disease, GO:0009013 is a focus for both basic and translational research. Advances in CRISPR gene editing now allow precise manipulation of the genes encoding this activity, enabling researchers to model loss-of-function, point mutations, and overexpression in relevant cell types [6,7]. This article provides a comprehensive overview of the mechanism, key genes, regulatory features, disease associations, and research methods for studying succinate-semialdehyde dehydrogenase [NAD(P)+] activity.
succinate-semialdehyde dehydrogenase [NAD(P)+] activity At A Glance
| GO ID | GO:0009013 |
|---|---|
| GO term | succinate-semialdehyde dehydrogenase [NAD(P)+] activity |
| Ontology | molecular_function |
| Synonym | succinate semialdehyde dehydrogenase (nicotinamide adenine dinucleotide (phosphate)); succinate-semialdehyde:NAD(P)+ oxidoreductase activity |
| Major function | Oxidation of succinate semialdehyde to succinate using NAD+ or NADP+ as cofactor |
| Reaction | succinate semialdehyde + NAD(P)+ + H2O = succinate + NAD(P)H + H+ |
| Cofactor | NAD+ or NADP+ |
| Pathway | GABA catabolism; TCA cycle anaplerosis |
| Enzyme family | Aldehyde dehydrogenase superfamily |
What Is GO:0009013?
GO:0009013, succinate-semialdehyde dehydrogenase [NAD(P)+] activity, is defined as the catalysis of the reaction: succinate semialdehyde + NAD(P)+ + H2O = succinate + NAD(P)H + H+. This means the enzyme transfers a hydride from succinate semialdehyde to either NAD+ or NADP+, producing succinate, the reduced cofactor, and a proton. The activity is synonymous with succinate semialdehyde dehydrogenase (nicotinamide adenine dinucleotide (phosphate)) and succinate-semialdehyde:NAD(P)+ oxidoreductase activity.
Why Is succinate-semialdehyde dehydrogenase [NAD(P)+] activity Important in Cell Biology?
GO:0009013 is essential for maintaining metabolic balance and neurotransmitter homeostasis. By converting succinate semialdehyde to succinate, it prevents the accumulation of toxic aldehydes and channels carbon into the TCA cycle [1,6]. In humans, loss of this activity causes succinic semialdehyde dehydrogenase deficiency, a disorder characterized by developmental delay, hypotonia, and seizures [7,8]. The activity is also a target for understanding oxidative stress, as lipid peroxidation products can inhibit the enzyme. Furthermore, bacterial and plant homologs inform biotechnology and evolutionary studies [1,2,4].
• Maintains GABA homeostasis by preventing succinate semialdehyde accumulation.
• Links neurotransmitter catabolism to energy production via the TCA cycle.
• Deficiency causes a rare neurometabolic disorder with severe neurological symptoms [7,8].
• Enzyme activity is sensitive to oxidative stress and lipid peroxidation products.
• Bacterial and plant enzymes provide models for enzyme evolution and biotechnology [1,2,4].
• The activity is a potential therapeutic target for epilepsy and metabolic disorders.
• CRISPR models enable precise study of gene variants affecting enzyme stability and function.
• Histochemical methods allow localization of activity in tissues.
• Adaptive laboratory evolution can exploit the promiscuity of this enzyme to repair metabolic deficiencies.
• Understanding the activity aids in interpreting genetic variants of uncertain significance.
What Happens During succinate-semialdehyde dehydrogenase [NAD(P)+] activity?
Substrate Binding and Cofactor Selection
In simple terms: The enzyme grabs succinate semialdehyde and either NAD+ or NADP+ to start the reaction.
The enzyme binds succinate semialdehyde and a nicotinamide cofactor (NAD+ or NADP+) in its active site. Structural studies of the Salmonella typhimurium YneI enzyme show that it can utilize both NAD+ and NADP+, with specific residues determining cofactor preference. In Escherichia coli, distinct NAD- and NADP-specific succinate-semialdehyde dehydrogenases have been separated and characterized, indicating that cofactor specificity can vary among homologs.
Hydride Transfer and Succinate Formation
In simple terms: A hydride ion is moved from the aldehyde to the cofactor, turning succinate semialdehyde into succinate.
The catalytic mechanism involves the transfer of a hydride from the aldehyde carbon of succinate semialdehyde to the nicotinamide ring of NAD(P)+, forming NAD(P)H. A water molecule participates in the reaction, and the product succinate is released. This oxidation is characteristic of aldehyde dehydrogenases and is essential for detoxifying the aldehyde [1,2].
Role in GABA Catabolism
In simple terms: This reaction is a key step in breaking down the brain chemical GABA.
In the GABA shunt, GABA is transaminated to succinate semialdehyde, which is then oxidized to succinate by succinate-semialdehyde dehydrogenase. This step links GABA degradation to the TCA cycle, providing energy and preventing aldehyde toxicity. In humans, the enzyme encoded by ALDH5A1 is responsible for this activity, and its deficiency leads to accumulation of GABA and succinate semialdehyde [7,8].
Enzyme Purification and Assays
In simple terms: Scientists measure this activity by tracking how much NADH or NADPH is produced.
Activity assays typically monitor the reduction of NAD+ or NADP+ spectrophotometrically at 340 nm. Purification from potato tubers and E. coli has provided kinetic parameters and substrate specificity data [2,4]. Histochemical methods have also been developed to localize the activity in tissue sections, though methodological challenges exist.
Key Genes Involved in GO:0009013 succinate-semialdehyde dehydrogenase [NAD(P)+] activity
The following genes and proteins are directly associated with succinate-semialdehyde dehydrogenase [NAD(P)+] activity or its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH5A1 | Encodes the human succinate-semialdehyde dehydrogenase | Mutations cause SSADH deficiency; target for gene therapy [7,8] |
| YneI | NAD(P)+-dependent SSADH in Salmonella typhimurium | Structural and mechanistic studies |
| GabD | NAD-dependent SSADH in Escherichia coli | Cofactor specificity and metabolic engineering |
| SSADH1 | Plant SSADH (e.g., potato) | Stress response and amino acid metabolism |
| ABAT | GABA transaminase, upstream of SSADH | GABA shunt regulation |
| GAD1 | Glutamate decarboxylase, GABA synthesis | GABA metabolism context |
| GAD2 | Glutamate decarboxylase, GABA synthesis | GABA metabolism context |
| SLC6A1 | GABA transporter | GABA homeostasis |
| GABRA1 | GABA receptor subunit | Neurotransmission |
| ALDH2 | Related aldehyde dehydrogenase | Comparative enzymology |
| ALDH1A1 | Related aldehyde dehydrogenase | Comparative enzymology |
| ALDH3A1 | Related aldehyde dehydrogenase | Comparative enzymology |
| ALDH7A1 | Related aldehyde dehydrogenase | Comparative enzymology |
| NADSYN1 | NAD+ synthesis | Cofactor availability |
| NAMPT | NAD+ salvage | Cofactor availability |
| SIRT1 | NAD+-dependent deacetylase | Metabolic regulation |
| PPARGC1A | Mitochondrial biogenesis regulator | Metabolic context |
| MTOR | mTOR signaling | Growth and metabolism |
How Is succinate-semialdehyde dehydrogenase [NAD(P)+] activity Regulated?
The activity of succinate-semialdehyde dehydrogenase can be regulated at multiple levels. At the enzyme level, alkenal products of lipid peroxidation, such as 4-hydroxynonenal, inhibit SSADH activity, linking oxidative stress to reduced GABA catabolism. In bacteria, adaptive laboratory evolution has revealed that the promiscuity of SSADH can be recruited to repair metabolic deficiencies, suggesting that substrate specificity can be modulated. In humans, mutations in ALDH5A1, including a combination of a novel mutation and a missense SNP, affect enzyme activity and stability, indicating that genetic variation is a key regulatory mechanism. Additionally, NAD+ availability, which depends on pathways such as NAMPT and NADSYN1, can influence the reaction rate.
succinate-semialdehyde dehydrogenase [NAD(P)+] activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH5A1 | SSADH deficiency (neurometabolic disorder) | Knockout mouse, patient-derived iPSCs [7,8] |
| ALDH5A1 | Epilepsy and developmental delay | Point-mutation knock-in mice |
| YneI | Bacterial metabolic deficiency | Adaptive laboratory evolution |
| GabD | E. coli metabolic engineering | Knockout and overexpression |
| SSADH1 | Plant stress response | Overexpression in potato |
Succinic Semialdehyde Dehydrogenase Deficiency
Succinic semialdehyde dehydrogenase deficiency (SSADHD) is an autosomal recessive neurometabolic disorder caused by mutations in ALDH5A1, leading to loss of GO:0009013 activity [7,8]. Patients accumulate GABA and succinate semialdehyde, resulting in developmental delay, hypotonia, ataxia, and seizures. A combination of a novel ALDH5A1 mutation and a missense SNP has been shown to strongly affect enzyme activity and stability, highlighting the importance of genetic diagnosis. Liver-directed adenoviral gene transfer in a murine model of SSADH deficiency has been explored as a therapeutic approach, demonstrating proof of concept for gene therapy.
Oxidative Stress and Neurodegeneration
Inhibition of SSADH activity by alkenal products of lipid peroxidation, such as 4-hydroxynonenal, suggests that oxidative stress can impair GABA catabolism. This link may contribute to neurodegeneration in conditions associated with oxidative damage, although direct evidence in human disease is still emerging. The enzyme's sensitivity to oxidative modifications makes it a potential biomarker for redox imbalance.
Metabolic Reprogramming and Cancer
Altered GABA metabolism and TCA cycle anaplerosis are increasingly recognized in cancer. While direct evidence for GO:0009013 in cancer is limited, the activity's role in succinate production could influence oncometabolite levels. Adaptive laboratory evolution studies have shown that SSADH promiscuity can repair metabolic deficiencies, suggesting potential for metabolic engineering in disease models.
From succinate-semialdehyde dehydrogenase [NAD(P)+] activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ALDH5A1 cause GABA accumulation? | ALDH5A1 knockout cell line (e.g., HEK293) |
| How does a specific point mutation affect enzyme stability? | Point-mutation knock-in via CRISPR |
| Can wild-type ALDH5A1 rescue the deficiency? | Knock-in of tagged ALDH5A1 |
| What is the effect of enzyme overexpression on flux? | Overexpression of ALDH5A1 in neuronal cells |
| Which cofactor is preferred in a specific tissue? | Knockout of NAD/NADP-specific isoforms |
| Can SSADH promiscuity be exploited? | Directed evolution in bacteria |
How to Study the succinate-semialdehyde dehydrogenase [NAD(P)+] activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Spectrophotometric assay | NADH/NADPH production | Enzyme kinetics and inhibitor screening [1,2] |
| Histochemistry | Tissue localization of activity | Brain regional distribution |
| CRISPR knockout | Loss of gene function | Disease modeling |
| CRISPR point mutation | Effect of specific variants | Genotype-phenotype correlation |
| RNA-seq | Transcriptional changes | Pathway analysis |
| Metabolomics | GABA and succinate levels | Metabolic flux |
| X-ray crystallography | 3D structure | Mechanistic insights |
Enzymatic Activity Assays
The most direct method to measure GO:0009013 is a spectrophotometric assay monitoring NADH or NADPH production at 340 nm. This assay has been used to characterize purified enzymes from potato, E. coli, and Salmonella [1,2,4]. It can be adapted to cell lysates or tissue homogenates to assess endogenous activity.
Histochemical Detection
Histochemical methods can localize SSADH activity in tissue sections, but methodological problems such as diffusion and nonspecific staining must be controlled. These techniques are useful for studying regional distribution in the brain.
Genetic and Genomic Approaches
CRISPR-Cas9 knockout, point mutation, and knock-in models allow precise manipulation of ALDH5A1 and its homologs. These models can be combined with RNA-seq to assess transcriptional changes and with metabolomics to measure GABA and succinate levels [6,7].
Structural Biology
X-ray crystallography and homology modeling of YneI and other SSADH enzymes have revealed the active site architecture and cofactor binding residues, informing inhibitor design and mechanistic studies.
How CRISPR Can Be Used to Study GO:0009013 succinate-semialdehyde dehydrogenase [NAD(P)+] activity
Knockout
CRISPR-Cas9 knockout of ALDH5A1 or its homologs creates cell and animal models of SSADH deficiency. These models recapitulate the accumulation of succinate semialdehyde and GABA, enabling studies of downstream effects and potential therapies [7,8].
Point Mutation
Introducing specific patient mutations, such as the novel ALDH5A1 mutation combined with a missense SNP, allows researchers to dissect the impact on enzyme activity and stability. This approach is valuable for classifying variants of uncertain significance.
Knock-in
Knock-in of tagged or fluorescently labeled ALDH5A1 enables live-cell imaging and proteomic analysis. It can also be used to restore wild-type function in deficient cells for rescue experiments.
Overexpression
Overexpression of ALDH5A1 or bacterial SSADH can increase flux through the GABA shunt, providing insights into metabolic regulation and potential biotechnological applications.
How EDITGENE Supports succinate-semialdehyde dehydrogenase [NAD(P)+] activity Research
Researchers studying succinate-semialdehyde dehydrogenase [NAD(P)+] activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or neurological phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research, from gene knockout to precise point mutations and overexpression.
Contact EDITGENE today to design your custom CRISPR model for succinate-semialdehyde dehydrogenase [NAD(P)+] activity research.
Frequently Asked Questions About succinate-semialdehyde dehydrogenase [NAD(P)+] activity
What is succinate-semialdehyde dehydrogenase [NAD(P)+] activity?
It is the enzymatic activity defined by GO:0009013 that converts succinate semialdehyde to succinate using NAD+ or NADP+ as a cofactor.
What genes are involved in succinate-semialdehyde dehydrogenase [NAD(P)+] activity?
The main human gene is ALDH5A1; bacterial homologs include YneI and GabD, and plant enzymes are found in potato [1,2,4,7].
What diseases are associated with succinate-semialdehyde dehydrogenase deficiency?
Mutations in ALDH5A1 cause succinic semialdehyde dehydrogenase deficiency, a neurometabolic disorder with developmental delay and seizures [7,8].
How is succinate-semialdehyde dehydrogenase activity measured?
It is typically measured by spectrophotometric assays monitoring NADH or NADPH production at 340 nm [1,2].
What is the role of GO:0009013 in GABA metabolism?
It catalyzes the final step of GABA catabolism, converting succinate semialdehyde to succinate and feeding into the TCA cycle.
Can CRISPR be used to study succinate-semialdehyde dehydrogenase activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of ALDH5A1 and homologs [6,7].
What are the cofactors for succinate-semialdehyde dehydrogenase?
The enzyme can use either NAD+ or NADP+ as an electron acceptor [1,4].
Is succinate-semialdehyde dehydrogenase activity inhibited by oxidative stress?
Yes, alkenal products of lipid peroxidation such as 4-hydroxynonenal inhibit the enzyme.
What model organisms are used to study SSADH deficiency?
Mouse models and patient-derived cells are commonly used, along with bacterial and plant systems for enzymology [2,4,8].
How does EDITGENE support research on GO:0009013?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression, library screening, and bioinformatics services for genes related to this activity.
Conclusion
Succinate-semialdehyde dehydrogenase [NAD(P)+] activity (GO:0009013) is a fundamental enzymatic function that bridges GABA catabolism and energy metabolism. Its dysfunction leads to a rare but severe neurometabolic disorder, and its modulation by oxidative stress has broader implications. Advances in CRISPR technology now enable precise modeling of genetic variants, offering new avenues for therapeutic development. EDITGENE's comprehensive services empower researchers to dissect this activity in health and disease.
References
- 1. Zheng H et al.. 2013. Structure and activity of the NAD(P)+-dependent succinate semialdehyde dehydrogenase YneI from Salmonella typhimurium.. Proteins 81(6):1031-41 PMID: 23229889
- 2. Satya Narayan V et al.. 1989. Potato tuber succinate semialdehyde dehydrogenase: purification and characterization.. Arch Biochem Biophys 275(2):469-77 PMID: 2596851
- 3. Bernocchi G et al.. 1983. Methodological problems in the histochemical demonstration of succinate semialdehyde dehydrogenase activity.. Histochem J 15(12):1161-76 PMID: 6643116
- 4. Cozzani I et al.. 1980. Separation and characterization of NAD- and NADP-specific succinate-semialdehyde dehydrogenase from Escherichia coli K-12 3300.. Biochim Biophys Acta 613(2):309-17 PMID: 7004491
- 5. Nguyen E et al.. 2003. Inhibition of succinic semialdehyde dehydrogenase activity by alkenal products of lipid peroxidation.. Biochim Biophys Acta 1637(1):107-12 PMID: 12527414
- 6. He H et al.. 2024. Adaptive laboratory evolution recruits the promiscuity of succinate semialdehyde dehydrogenase to repair different metabolic deficiencies.. Nat Commun 15(1):8898 PMID: 39406738
- 7. Menduti G et al.. 2018. Succinic semialdehyde dehydrogenase deficiency: The combination of a novel ALDH5A1 gene mutation and a missense SNP strongly affects SSADH enzyme activity and stability.. Mol Genet Metab 124(3):210-215 PMID: 29895405
- 8. Gupta M et al.. 2004. Liver-directed adenoviral gene transfer in murine succinate semialdehyde dehydrogenase deficiency.. Mol Ther 9(4):527-39 PMID: 15093183
